TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03978039
Drug: Immunotherapeutic Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as per standard of care
Study: NCT03978039
Drug: target treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as per standard of care
Study: NCT05321329
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.Capecitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of capecitabine is as a Nucleic Acid Synthesis Inhibitor.
Study: NCT01247064
Drug: Nebulized 3% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of nebulized 3% saline once
Study: NCT01247064
Drug: Nebulized 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of 0.9% nebulized normal saline once
Study: NCT02160288
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispensed in a 5 cc syringe
Study: NCT01138514
Drug: Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to the entire face twice daily for 10 weeks
Study: NCT01138514
Drug: Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to the entire face twice daily for 10 weeks
Study: NCT01138514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00938301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIC matching in appearance to PF-04455242 will be used to administer placebo.
Study: NCT01444300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill, bid for 12 weeks
Study: NCT02266160
Drug: EMLA cream 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days.
Study: NCT02070653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00490542
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
Study: NCT00293176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching placebo tablets.
Study: NCT00006379
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide IV over 2 hours on days -3 to -2
Study: NCT01589614
Drug: PH-797804 + erythromycin
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
Study: NCT00125788
Drug: L-glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Study: NCT00125788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Study: NCT00688714
Drug: AZD6482
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9-364,5 mg administrated through intravenous infusion over 3 hours
Study: NCT00688714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02112656
Drug: ThermoDox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
Study: NCT02112656
Drug: Dummy infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
Study: NCT01981681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study: NCT01981681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study: NCT00914576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules/day for 14 days
Study: NCT04676906
Drug: NNC0113-6861
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study compound 1 - Each participant will receive a single intravenous (i.v) dose of \[14C\]-NNC0113-6861
Study: NCT04676906
Drug: NNC0113-6860
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study compound 2 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6860
Study: NCT04676906
Drug: NNC0113-6891
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study compound 3 - Each participant will receive a single i.v dose of \[14C\]-NNC0113-6891
Study: NCT00003842
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03102567
Drug: GLPG1205 50mg q.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
Study: NCT03102567
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
Study: NCT03326245
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PL will be given 30 minutes prior to bolus \[11C\]raclopride injection
Study: NCT03326245
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Placebo given 30 minutes post bolus injection of \[11C\]raclopride.
Study: NCT01047189
Drug: clindamycin 1% gel
Normalized name: BENZOYL PRX 5%/CLINDAMYCIN 1% GEL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin applied each morning for 12 weeks
Study: NCT01047189
Drug: tretinoin 0.025% cream
Normalized name: TRETINOIN 0.025% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.025% cream each evening for 12 weeks
Study: NCT00706147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo capsules given three times per day
Study: NCT01750853
Drug: LY3045697
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01750853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01544673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral placebo twice daily for 4.5 days
Study: NCT03522064
Drug: Testosterone Enanthate 100 MG/ML Injectable Solution
Normalized name: testosterone enanthate 100 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
Study: NCT03522064
Drug: Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL. Carboplatin as per standard procedures
Study: NCT01561911
Drug: Chi Lob 7/4 (A chimeric monoclonal antibody)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
Study: NCT01451411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT03102567
Drug: GLPG1205 250 loading dose and 50mg q.d. maintenance dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
Study: NCT02266563
Drug: Amyvid PET Scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
Study: NCT02266563
Drug: T807 PET scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
Study: NCT00605059
Drug: [123I]AV94
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Study: NCT00577200
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil
Study: NCT02865174
Drug: Floseal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
Study: NCT01662908
Drug: enoxaparin/unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
Study: NCT03796910
Drug: Placebo for SAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
Study: NCT03796910
Drug: SPR720 for MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
Study: NCT03796910
Drug: Placebo for MAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
Study: NCT02762266
Drug: embolic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: . Acceptable embolic agents include:~* Gelatin sponge (gelfoam)~* Polyvinyl alcohol (PVA) particles~* Microspheres / Embolic beads
Study: NCT00428896
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
Study: NCT03398330
Drug: OxyContin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally taking OXYCONTIN® 40mg in fed state
Study: NCT00773084
Drug: Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
Study: NCT04350684
Drug: Standards of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: This Drug will be used in all arms as mandated by our governmental guidelines.
Study: NCT04577781
Drug: GLPG3970
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.
Study: NCT04577781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo powder and solvent for oral solution to be reconstituted prior to use.
Study: NCT01812057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% -5 ml
Study: NCT00811460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc for 4 days
Study: NCT01814956
Drug: Lipoplus 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
Study: NCT01814956
Drug: Lipofundin N 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
Study: NCT01657305
Drug: Oleogel-S10, non-adhesive wound dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
Study: NCT00617864
Drug: Human Albumin Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group will receive single infusion of albumin at the time of oocyte retrieval.
Study: NCT00617864
Drug: Saline Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group will receive single infusion of saline at the time of oocyte retrieval.
Study: NCT00578097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection cycle, intradetrusor injection at baseline (visit 2).
Study: NCT02421094
Drug: GR-MD-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-MD-02 active
Study: NCT02421094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00487916
Drug: AMA1-C1/ISA 720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01126957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given as an bolus to control group.
Study: NCT01126957
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
Study: NCT02375100
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
Study: NCT00287924
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03224039
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal for one dose (experimental)
Study: NCT03224039
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
Study: NCT00820547
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
Study: NCT00820547
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
Study: NCT01205503
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
Study: NCT01205503
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
Study: NCT02765399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04846335
Drug: Doxycycline Hcl
Normalized name: doxycycline HCl
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets of DOXY hydrocloride (Bassado)
Study: NCT04846335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets of placebo
Study: NCT03358030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT00716274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily, for 16 weeks
Study: NCT01932788
Drug: Placebo gummy vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
Study: NCT00405288
Drug: Proctofoam-HC®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observational study of the exposure to Proctofoam-HC®
Study: NCT01193452
Drug: S-1, Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week.
Study: NCT01193452
Drug: leucovorin, 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks
Study: NCT02394158
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02323230
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose cyclophosphamide will be taken by mouth
Study: NCT02109614
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator arm will be taking 1500mg of the placebo daily
Study: NCT02723084
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-formulated tablet
Study: NCT02470702
Drug: Placebo (D5W)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04930679
Drug: Andiabet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each hard capsule includes: 200mg Gynostemma Pentaphyllum Leaf, 200mg Largerstroemia Speciosa Leaf, 133mg Anemarrhena Asphodeloides Whole
Study: NCT01342926
Drug: GSK933776
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK933776
Study: NCT01342926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00002593
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV as described in Arm Description
Study: NCT00002593
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV as described in Arm description.
Study: NCT04422431
Drug: Bis-Choline Tetrathiomolybdate
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
Study: NCT00654173
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00654173
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00752414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: same frequency as MP-376
Study: NCT03695445
Drug: Peripheral administration of Norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic follow-up of complications from peripheral administration of Norepinephrine
Study: NCT02199041
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by intravenous infusion as part of the preparative regimen.
Study: NCT01161914
Drug: Cerezyme®
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by IV infusion for a dose of 60 U/kg
Study: NCT01161914
Drug: ISU302
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by IV infusion for a dose of 60 U/kg
Study: NCT03041935
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT03041935
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT00366145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 infusions per week for 4 weeks
Study: NCT00366145
Drug: Standard of Care for GVHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)